Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2016 Feb 1;62(3):362-8. doi: 10.1093/cid/civ885. Epub 2015 Oct 20.

Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

Author information

  • 1Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • 2Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, India.
  • 3Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Abstract

Azole resistance in Aspergillus fumigatus has emerged as a global health problem. Although the number of cases of azole-resistant aspergillosis is still limited, resistance mechanisms continue to emerge, thereby threatening the role of the azole class in the management of diseases caused by Aspergillus. The majority of cases of azole-resistant disease are due to resistant A. fumigatus originating from the environment. Patient management is difficult due to the absence of patient risk factors, delayed diagnosis, and limited treatment options, resulting in poor treatment outcome. International and collaborative efforts are required to understand how resistance develops in the environment to allow effective measures to be implemented aimed at retaining the use of azoles both for food production and human medicine.

KEYWORDS:

aspergilloma; azole fungicides; chronic pulmonary aspergillosis; emergence of azole resistance; invasive aspergillosis

PMID:
26486705
PMCID:
PMC4706635
DOI:
10.1093/cid/civ885
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center